MarginsXMarginsX
Home › Markets › Health Care › OKYO

OKYO Pharma Limited (OKYO)

OKYO trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.18
-12.96% on the day
Market cap
$61.7M
Micro cap
Revenue
Foreign filer: no machine-readable annual figure in SEC data
Net income
Foreign filer: no machine-readable annual figure in SEC data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerOKYO on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryGuernsey
IPO year2022
SEC CIK0001849296
SEC industry codeBiological Products, (No Diagnostic Substances)

Financials

Foreign filer: no machine-readable annual figure in SEC data.

Warning signs

Cash runway
29.5 months
$14.6M cash at March 31, 2026
Share count, 1 year
+39.5%
2025-07-03 to 2026-07-15 · +105.4% over 3 years
Going-concern doubt
No
20-F filed July 20, 2026
Insider net buying, 12 months
$136K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.20-F 2026-07-20
Cash and burn$14.6M cash; operating cash flow -$1.5M a quarter.Report 2026-03-31
Shares outstanding52,479,527 (2026-07-15); 37,610,676 a year earlier; 25,553,274 three years earlier.Cover page 2026-07-15
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the marketLatest 2026-02-17
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPKF Littlejohn LLP, London, United KingdomPCAOB Form AP 2026-07-27
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $136K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2026
2026-03-31
Not filed-$8.9M-$5.9M$14.6MNo debt tagsNeeds four quarters20-F 2026-07-20
FY 2025
2025-03-31
Not filed-$4.7M-$1.8M$1.6M$2.7MNeeds four quarters20-F 2025-07-18
FY 2024
2024-03-31
Not filed-$16.8M-$9.5M$827KNo debt tagsNeeds four quarters20-F 2025-07-18
FY 2023
2023-03-31
Not filed-$13.3M-$7.7M$4.0MNo debt tagsNeeds four quarters20-F 2025-07-18
FY 2022
2022-03-31
Not filed-$5.4M-$5.5M$2.7MNo debt tagsNeeds four quarters20-F 2024-08-13
FY 2021
2021-03-31
Not filed-$3.4M-$1.6M$6.9MNo debt tagsNeeds four quarters20-F 2023-08-15
FY 2020
2020-03-31
Not filed-$1.5M-$1.2M$235KNo debt tagsNeeds four quarters20-F 2022-08-15

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-02-17
Latest annual report20-F2026-07-20
Latest quarterly / interim6-K2026-11-12

Source: SEC EDGAR submissions feed, 312 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-5.6%
1 month-6.1%
3 months-10.6%
Year to date-34.8%
1 year-43.5%
From 52-week high-56.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
CGTXCognition Therapeutics Inc.$0.6388-6.03%$60.8M
PMCBPharmaCyte Biotech Inc.$5.57-16.62%$59.8M
CSBRChampions Oncology Inc.$4.68-0.53%$65.1M
ATRAAtara Biotherapeutics Inc.$6.40-16.88%$65.2M
CRDFCardiff Oncology Inc.$0.8477+16.75%$65.9M
NMRANeumora Therapeutics Inc.$0.3695-13.85%$69.4M
GRMLGreenland Mines Ltd.$3.50-3.05%$51.9M
ELOXEloxx Pharmaceuticals Inc.$12.75-3.04%$51.5M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier